The Human Genome Project attracted investment beyond what a rational analysis would have predicted. There are pros and cons to that, says Philip Ball. If a venture capitalist had invested in sequencing the human genome, what would she have to show for it? For scientists, the Human Genome Project (HGP) might lay the foundation of tomorrow's medicine, with drugs tailored to your genetics. But a venture capitalist would want medical innovations here and now, not decades hence. Nearly ten years after the project's formal completion, there's not much sign of them.A team of researchers in Switzerland now argue that the...